LINC01168

Across TCGA pan-cancer cohorts, LINC01168 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated LINC01168 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01168 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01168 expression acts as an unfavorable survival marker, although some lineages such as MESO and SARC show a favorable association.

LUAD, MESO, and SARC are the cancer types where LINC01168 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.446	0.835	.001	78	view →
MESO	OS	Median	III,IV	0.677	0.441	.001	37	view →
SARC	DFS	Quartile	All	0.655	0.421	<.001	37	view →
UCEC	OS	Tertile	All	0.893	0.933	.016	36	view →
CHOL	DFS	Tertile	II,III,IV	0.090	0.493	<.001	35	view →
COAD	DFS	Quartile	IV	0.318	0.575	.003	35	view →
THCA	OS	Tertile	All	0.965	0.991	.011	34	view →
ACC	DFS	Tertile	III,IV	0.178	0.523	.017	27	view →
LGG	OS	Tertile	All	0.943	0.832	<.001	26	view →
STAD	OS	Median	III,IV	0.212	0.469	.014	25	view →
THYM	DFS	Tertile	All	0.583	0.806	.010	18	view →
CESC	OS	Median	II,III,IV	0.890	0.766	.026	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

LINC01168–LUAD (DFS)

Open the LUAD breakdown →